Charles E. Geyer, MD

Charles E. Geyer, MD, is a professor of medicine and chief of Malignant Hematology and Medical Oncology in the Department of Medicine at the University of Pittsburgh and the University of Pittsburgh Medical Center Hillman Cancer Center

Articles by Charles E. Geyer, MD

Dr Geyer on the FDA Approval of T-DXd Followed by THP for HER2+ Breast Cancer

ByCharles E. Geyer, MD

June 30th 2026

Charles E. Geyer, MD, discusses the significance of the FDA approval of neoadjuvant T-DXd followed by THP for patients with HER2-positive breast cancer.

Dr Geyer on the FDA Approval of Post-Neoadjuvant T-DXd for HER2+ Breast Cancer

ByCharles E. Geyer, MD

June 30th 2026

Charles E. Geyer, MD, highlights data that led to the FDA approval of post-neoadjuvant T-DXd for patients with HER2-positive breast cancer.

Charles E. Geyer, MD

Articles by Charles E. Geyer, MD

Dr Geyer on the FDA Approval of T-DXd Followed by THP for HER2+ Breast Cancer

Dr Geyer on the FDA Approval of Post-Neoadjuvant T-DXd for HER2+ Breast Cancer

Latest Updated Articles

Trending on OncLive

FDA Approves Orca-T for Matched Donor HSCT in Hematologic Malignancies

FDA Issues CRL to PET Diagnostic Imaging Kit for Gallium-68 Edotreotide in SSTR+ NETs

Epcoritamab Plus Lenalidomide Improves PFS vs R-GemOx in R/R DLBCL

MANGROVE Trial Shows Improved Efficacy With Zanubrutinib Plus Rituximab vs Chemo in MCL

Experts Outline the Evolving Role of ctDNA-Based MRD Testing Across Solid Tumors